Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01522820
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:25.185987+00:00
Published At
2016-10-04T00:00:00+00:00
Record Updated At
2016-10-04
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2016-10-04"
protocolSection.identificationModule.nctId
"NCT01522820"
protocolSection.identificationModule.officialTitle
"A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Anaplastic Astrocytoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Oligoastrocytoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Oligodendroglioma (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Negative (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Positive (protocolSection.conditionsModule.conditions)
  • Glioblastoma (protocolSection.conditionsModule.conditions)
  • Hormone-Resistant Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Prostate Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Renal Cell Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Brain Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Bladder Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Colorectal Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Esophageal Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Gastric Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Melanoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Prostate Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Uterine Corpus Carcinoma (protocolSection.conditionsModule.conditions)
  • Resectable Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Sarcoma (protocolSection.conditionsModule.conditions)
  • Stage IA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IA Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IB Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage II Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIA Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIB Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIB Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIB Skin Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IIC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIC Skin Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IIIA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Skin Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IIIA Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Skin Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IIIB Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Skin Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IIIC Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Bladder Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Skin Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IVA Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)
  • Stage IVB Uterine Corpus Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.